BIOTECH ONE
Simplifying complex biomanufacturing through innovative design
Welcome to Biotech One, a pioneering biotechnology startup paving the way for rapid, affordable and curative immunotherapies.
We are a team of determined individuals, sharing a vision for creating cutting edge manufacturing solutions that make advanced therapies affordable for all. We believe that our groundbreaking technology has the potential to become an industry disruptor and rapidly deliver immunotherapies to patients with unmet needs on a global scale.
"Chance favors the prepared mind,” Dr. Carl June says in “Of Medicine and Miracles,” recalling the scientist Louis Pasteur’s famous quote about how he would often stumble upon his breakthroughs in vaccination and disease prevention.
Manufacturing CAR T cells in the current setting is unnecessarily lengthy, redundant and expensive. The length of time between apheresis collection and re-infusion of CAR T cells is sub optimal for patients with rapidly progressive disease. COGS are high in CAR T products due to a labor-intensive process, expensive cGMP manufacturing space, and costly supplies and reagents.
Biotech One provides an innovative approach to stably express CARs in quiescent T cells based on the groundbreaking work of Dr. Ghassemi and Dr. O'Connor . By eliminating the activation step and optimizing the delivery of CAR transgenes into non-activated T cells, Biotech One can generate clinically potent CAR T cells with cytolytic activity against cancer within 24 hours. The reduced manufacturing complexity allows for treatment of larger patient populations, with an estimated 3 fold reduction in cost and a 10 fold decrease in time to patients.​
BOLDLY DELIVERING DISRUPTIVE INNOVATION